ECSP12012180A - Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar - Google Patents

Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar

Info

Publication number
ECSP12012180A
ECSP12012180A ECSP12012180A ECSP12012180A EC SP12012180 A ECSP12012180 A EC SP12012180A EC SP12012180 A ECSP12012180 A EC SP12012180A EC SP12012180 A ECSP12012180 A EC SP12012180A
Authority
EC
Ecuador
Prior art keywords
peptide
auxiliary
coupled
amiloid
beta
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Ana Graf
Peter Ulrich
Katja Baer
Georges Imbert
Marie Jose Hoellinger
Marie Emmanuelle Riviere
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012180(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP12012180A publication Critical patent/ECSP12012180A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ECSP12012180 2010-03-29 2012-09-25 Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar ECSP12012180A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
US36169710P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
ECSP12012180A true ECSP12012180A (es) 2012-10-30

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012180 ECSP12012180A (es) 2010-03-29 2012-09-25 Composición que comprende el péptido amiloide beta 1-6 acoplado a una partícula similar a virus y un auxiliar

Country Status (24)

Country Link
US (4) US20130011431A1 (enExample)
EP (1) EP2552489A1 (enExample)
JP (2) JP6088422B2 (enExample)
KR (1) KR20130018407A (enExample)
CN (2) CN102834118A (enExample)
AR (1) AR080810A1 (enExample)
AU (1) AU2011234656B2 (enExample)
BR (1) BR112012024708A2 (enExample)
CA (1) CA2793580A1 (enExample)
CL (1) CL2012002685A1 (enExample)
CO (1) CO6630127A2 (enExample)
EC (1) ECSP12012180A (enExample)
GT (1) GT201200265A (enExample)
IL (1) IL221540B (enExample)
MA (1) MA34084B1 (enExample)
MX (1) MX2012011340A (enExample)
NZ (1) NZ601729A (enExample)
PE (1) PE20130642A1 (enExample)
PH (1) PH12012501683A1 (enExample)
RU (1) RU2603486C2 (enExample)
SG (2) SG10201505374TA (enExample)
TN (1) TN2012000431A1 (enExample)
TW (2) TW201138805A (enExample)
WO (1) WO2011120924A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015165971A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
DK3137094T3 (da) * 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
KR102388363B1 (ko) * 2014-04-29 2022-04-19 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병(ad)의 치료 및 예방
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトAffiris Ag アルツハイマー病(ad)の処置および予防
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
WO2026155574A1 (ko) * 2025-01-15 2026-07-23 주식회사 포스백스 파필로마바이러스 바이러스 유사입자 기반 항-아밀로이드 베타 동물용 백신

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
CA2295740A1 (en) * 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
BR0312792A (pt) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
NZ554387A (en) * 2004-09-21 2009-09-25 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
US20150297692A1 (en) 2015-10-22
CO6630127A2 (es) 2013-03-01
RU2603486C2 (ru) 2016-11-27
SG10201505374TA (en) 2015-08-28
AU2011234656B2 (en) 2013-08-01
JP2013523682A (ja) 2013-06-17
PH12012501683A1 (en) 2012-11-05
EP2552489A1 (en) 2013-02-06
TW201618806A (zh) 2016-06-01
PE20130642A1 (es) 2013-06-19
US20130011431A1 (en) 2013-01-10
MX2012011340A (es) 2012-11-16
CA2793580A1 (en) 2011-10-06
CN104436212A (zh) 2015-03-25
JP6088422B2 (ja) 2017-03-01
TN2012000431A1 (en) 2014-01-30
JP2017008035A (ja) 2017-01-12
TW201138805A (en) 2011-11-16
CL2012002685A1 (es) 2013-01-25
BR112012024708A2 (pt) 2016-06-07
AR080810A1 (es) 2012-05-09
IL221540B (en) 2018-11-29
US20160101167A1 (en) 2016-04-14
SG183806A1 (en) 2012-10-30
MA34084B1 (fr) 2013-03-05
AU2011234656A1 (en) 2012-10-11
US20140348871A1 (en) 2014-11-27
KR20130018407A (ko) 2013-02-21
WO2011120924A1 (en) 2011-10-06
GT201200265A (es) 2014-03-14
CN102834118A (zh) 2012-12-19
NZ601729A (en) 2013-10-25
RU2012145734A (ru) 2014-05-10

Similar Documents

Publication Publication Date Title
CO6630127A2 (es) Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
MX2018013668A (es) Inhibidores de virus de hapatitis c.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
MX2016011686A (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
UY33897A (es) Inhibidores del virus de la hepatitis c
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
CU20150071A7 (es) Composición de liberación demorada que comprende biguanida
UA108858C2 (xx) Похідні ізоксалідину
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2019002133A1 (es) Partícula similar a virus (vlp).
HN2011000864A (es) Particulas inhalables que comprenden tiotropio
PH12013502177A1 (en) Hepatitis c virus inhibitors
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2016000300A1 (es) Métodos terapéuticos
UY35037A (es) Composición antiparasitaria de amplio espectro de nitazoxanida,probióticos y prebióticos
TN2015000093A1 (en) Isoxazolidine derivatives
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
UA113048C2 (xx) Противірусні сполуки
CR20140273A (es) Composiciones y métodos para tratar el virus de la hepatitis c